Ajovy (fremanezumab-vfrm) vs Nurtec ODT (rimegepant)

Ajovy (fremanezumab-vfrm) vs Nurtec ODT (rimegepant)

Ajovy (fremanezumab-vfrm) is a monoclonal antibody administered as a monthly or quarterly injection for the preventive treatment of migraine in adults, aiming to reduce the frequency of migraine days. Nurtec ODT (rimegepant) is an orally disintegrating tablet used for the acute treatment of migraine with or without aura in adults and for the preventive treatment of episodic migraine, offering both immediate relief and a preventive option taken every other day. When deciding between the two, patients should consider their preference for the mode of administration, the frequency of their migraine attacks, and whether they are seeking a treatment primarily for prevention (Ajovy) or one that can also address acute migraine episodes (Nurtec ODT).

Difference between Ajovy and Nurtec ODT

Metric Ajovy (fremanezumab-vfrm) Nurtec ODT (rimegepant)
Generic name Fremanezumab-vfrm Rimegepant
Indications Preventive treatment of migraine in adults Acute treatment of migraine with or without aura in adults
Mechanism of action Monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor Small molecule CGRP receptor antagonist
Brand names Ajovy Nurtec ODT
Administrative route Subcutaneous injection Orally disintegrating tablet
Side effects Injection site reactions, hypersensitivity reactions Nausea, somnolence, dry mouth, dyspepsia
Contraindications Hypersensitivity to fremanezumab-vfrm or to any of the excipients Hypersensitivity to rimegepant, or to any component of the product
Drug class Monoclonal antibody Calcitonin gene-related peptide (CGRP) receptor antagonist
Manufacturer AbbVie (previously Teva Pharmaceuticals) Biohaven Pharmaceuticals

Efficacy

Ajovy (fremanezumab-vfrm) Efficacy in Migraine Prevention

Ajovy (fremanezumab-vfrm) is a monoclonal antibody approved by the FDA for the preventive treatment of migraine in adults. Clinical trials have demonstrated its efficacy in reducing the monthly average number of migraine days. In these trials, patients treated with Ajovy experienced a significant reduction in migraine frequency compared to those on placebo. The medication is administered as a subcutaneous injection, which can be given either monthly or quarterly, providing flexibility in dosing. Ajovy works by targeting and blocking the calcitonin gene-related peptide (CGRP) pathway, which is believed to play a critical role in migraine pathophysiology.

Nurtec ODT (rimegepant) Efficacy in Acute Migraine Treatment

Nurtec ODT (rimegepant) is an orally disintegrating tablet indicated for the acute treatment of migraine with or without aura in adults. It is a CGRP receptor antagonist that provides rapid relief from migraine pain and associated symptoms. Clinical studies have shown that a significant proportion of patients taking Nurtec ODT reported pain freedom and absence of the most bothersome migraine symptom within two hours of taking the medication. Moreover, the benefits of Nurtec ODT include a sustained effect, with many patients achieving relief that lasts up to 48 hours post-dose.

Comparative Efficacy in Migraine Management

When comparing Ajovy and Nurtec ODT, it is important to note that they are used for different aspects of migraine management. Ajovy is designed for preventive treatment, aiming to reduce the frequency of migraine attacks over time, while Nurtec ODT is used for the immediate relief of migraine symptoms during an attack. Both medications have shown high efficacy in their respective roles, with Ajovy being beneficial for patients seeking to decrease the number of migraine days per month, and Nurtec ODT being effective for patients needing prompt relief from acute migraine pain and symptoms.

Considerations for Use in Migraine Patients

When considering the use of Ajovy or Nurtec ODT for migraine treatment, it is essential to evaluate the patient's individual needs, migraine frequency, and response to previous treatments. Both medications are generally well-tolerated, but as with any medication, they may not be suitable for everyone. Patients with a history of hypersensitivity to the active ingredients or to any of the excipients should not use these medications. It is also important to consider potential interactions with other medications the patient may be taking. Healthcare providers should provide a comprehensive assessment to determine the most appropriate treatment plan for their patients with migraine.

Regulatory Agency Approvals

Ajovy
  • European Medical Agency (EMA), European Union
  • Food and Drug Administration (FDA), USA
  • Health Canada
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Therapeutic Goods Administration (TGA), Australia
Nurtec ODT
  • Food and Drug Administration (FDA), USA

Access Ajovy or Nurtec ODT today

If Ajovy or Nurtec ODT are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email:

Contact us
US 0